Abstract
Background: Mitochondria are cellular organelles responsible for energy production, calcium handling, controlled synthesis of reactive oxygen species (ROS), and regulation of apoptosis. All these functions are crucial for cardiac homeostasis, and may be impaired in chronic heart failure (CHF). Therefore, mitochondrial dysfunction might represent a crucial element in the onset and progression of CHF and, as such, a promising therapeutic target.
Methods: Original articles and review on the treatment of mitochondrial dysfunction in CHF were searched on Medline and Scopus.
Results: The present review summarizes the current knowledge about mitochondrial modulation as a therapeutic strategy for CHF, and proposes some perspectives for future studies. Mitochondrial dysfunction can be ascribed to neuro-humoral activation and cardiac remodeling associated with CHF. Conceptually, the correction of mitochondrial dysfunction could provide an additive benefit to optimal CHF treatment. Increasing glucose metabolism and reducing oxidative stress within mitochondria are the two most promising approaches, even though further studies are required before implementing new treatments in the setting of CHF. On the other hand, inhibition of apoptosis, and normalization of calcium and mitochondrial dynamics have been assessed almost exclusively in ex vivo models, and mostly in settings other than CHF.
Conclusion: Mitochondrial modulation in CHF is an intriguing example of translational research and a potentially rewarding field.
Keywords: Heart failure, therapy, mitochondria, metabolism, calcium, apoptosis.
Current Pharmaceutical Design
Title:Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches
Volume: 22 Issue: 31
Author(s): Alberto Aimo, Chiara Borrelli, Giuseppe Vergaro, Massimo F. Piepoli, Alberto R. De Caterina, Gianluca Mirizzi, Alessandro Valleggi, Valentina Raglianti, Claudio Passino, Michele Emdin and Alberto Giannoni
Affiliation:
Keywords: Heart failure, therapy, mitochondria, metabolism, calcium, apoptosis.
Abstract: Background: Mitochondria are cellular organelles responsible for energy production, calcium handling, controlled synthesis of reactive oxygen species (ROS), and regulation of apoptosis. All these functions are crucial for cardiac homeostasis, and may be impaired in chronic heart failure (CHF). Therefore, mitochondrial dysfunction might represent a crucial element in the onset and progression of CHF and, as such, a promising therapeutic target.
Methods: Original articles and review on the treatment of mitochondrial dysfunction in CHF were searched on Medline and Scopus.
Results: The present review summarizes the current knowledge about mitochondrial modulation as a therapeutic strategy for CHF, and proposes some perspectives for future studies. Mitochondrial dysfunction can be ascribed to neuro-humoral activation and cardiac remodeling associated with CHF. Conceptually, the correction of mitochondrial dysfunction could provide an additive benefit to optimal CHF treatment. Increasing glucose metabolism and reducing oxidative stress within mitochondria are the two most promising approaches, even though further studies are required before implementing new treatments in the setting of CHF. On the other hand, inhibition of apoptosis, and normalization of calcium and mitochondrial dynamics have been assessed almost exclusively in ex vivo models, and mostly in settings other than CHF.
Conclusion: Mitochondrial modulation in CHF is an intriguing example of translational research and a potentially rewarding field.
Export Options
About this article
Cite this article as:
Aimo Alberto, Borrelli Chiara, Vergaro Giuseppe, Piepoli F. Massimo, Caterina R. De Alberto, Mirizzi Gianluca, Valleggi Alessandro, Raglianti Valentina, Passino Claudio, Emdin Michele and Giannoni Alberto, Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches, Current Pharmaceutical Design 2016; 22 (31) . https://dx.doi.org/10.2174/1381612822666160701075027
DOI https://dx.doi.org/10.2174/1381612822666160701075027 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antiangiogenic Therapeutic Approaches in Multiple Myeloma
Current Cancer Drug Targets Theoretical and Evidence-Based Benefit of Afterload Reduction in the Postoperative Pediatric Heart
Current Vascular Pharmacology Crystallization and Preliminary X-Ray Analysis of the Highly Thermostable Sweet Protein Mabinlin II
Protein & Peptide Letters Pitavastatin Improves Endothelial Function and Glucose Metabolism in Ovariectomized Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Inhibition of Interleukin-1 in the Treatment of Selected Cardiovascular Complications
Current Reviews in Clinical and Experimental Pharmacology Transition of Care for Patients with Diabetes
Current Diabetes Reviews Small Molecule Inhibitors of NF-κB and JAK/STAT Signal Transduction Pathways as Promising Anti-Inflammatory Therapeutics
Mini-Reviews in Medicinal Chemistry Lipids and Lysosomes
Current Drug Metabolism Pituitary Stem Cells Drop Their Mask
Current Stem Cell Research & Therapy Vasoproliferation and Antiproliferative Treatment Options in Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery Antiplatelet Therapy in Children: Why So Different from Adults’?
Current Pharmaceutical Design Integrins: A Method of Early Intervention in the Treatment of Colorectal Liver Metastases
Current Pharmaceutical Design Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Current Pharmaceutical Design Fenofibrate: A New Treatment for Diabetic Retinopathy. Molecular Mechanisms and Future Perspectives
Current Medicinal Chemistry Pre-hospital Fibrinolysis in the Management of Patients with ST Elevation Acute Coronary Syndrome: Review of the Evidence, Implementation and Future Directions
Cardiovascular & Hematological Disorders-Drug Targets Finding Drug Targets Through Analysis of the Platelet Transcriptome
Current Pharmaceutical Design Aldosterone, From (Patho)Physiology to Treatment in Cardiovascular and Renal Damage
Current Vascular Pharmacology Role of Innate Immune System in Inflammation and Cardiac Remodeling After Myocardial Infarction
Current Vascular Pharmacology Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Actions of Relaxin on Non-Reproductive Tissues
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents